Stocks and Investing
Stocks and Investing
Thu, February 23, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Stephanie Davis Upgraded (TDOC) to Buy and Held Target at $34 on, Feb 23rd, 2023
Stephanie Davis of SVB Leerink, Upgraded "Teladoc Health, Inc." (TDOC) to Buy and Held Target at $34 on, Feb 23rd, 2023.
Stephanie has made no other calls on TDOC in the last 4 months.
There are 7 other peers that have a rating on TDOC. Out of the 7 peers that are also analyzing TDOC, 5 agree with Stephanie's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Marc Solecitto of "Barclays" Maintained at Hold with Decreased Target to $28 on, Wednesday, January 18th, 2023
- Daniel Grosslight of "Citigroup" Maintained at Hold with Decreased Target to $33 on, Tuesday, December 13th, 2022
- Jonathan Yong of "Credit Suisse" Maintained at Hold with Decreased Target to $30 on, Monday, October 31st, 2022
- Steve Valiquette of "Barclays" Maintained at Hold with Decreased Target to $32 on, Thursday, October 27th, 2022
- Sandy Draper of "Guggenheim" Upgraded from Strong Sell to Hold on, Monday, October 24th, 2022
These are the ratings of the 2 analyists that currently disagree with Stephanie
- Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $37 on, Thursday, January 19th, 2023
- Robert Simmons of "DA Davidson" Maintained at Strong Buy with Decreased Target to $40 on, Tuesday, October 25th, 2022
Contributing Sources